Stay updated with breaking news from Compass Pathways. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Promising results from studies have sparked a wave of popular interest in psychedelics, amplified by writings touting their potential to reshape care for mental illness, and other care.
After half-a-century of prohibition, the United States is about to legalize psilocybin and MDMA for clinical use, to treat people suffering from post-traumatic stress disorder or terminal cancer. Scientists, patients, clandestine therapists and war veterans speak with EL PAÍS about the bright spots and shadows of this rebirth
Money is pouring into the fledgling psychedelic medicine industry, with dozens of startup companies vying to be among the first to sell mind-expanding drugs for depression, addiction and other mental health conditions.
Money is pouring into the fledgling psychedelic medicine industry, with dozens of startup companies vying to be among the first to sell mind-expanding drugs for depression, addiction and other mental health conditions.
COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) Director Ekaterina Malievskaia sold 19,853 shares of the business’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $10.59, for a total value of $210,243.27. Following the completion of the sale, the director now directly owns 4,144,994 shares in […]